Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules

Table 1 Respondent demographics

%	Patients switching from SGCs BID to Tablets BID (%)	Patients switching from SGCs BID or QD to Tablets QD (%)
Male/Female	85/15	76/24
Age:
> 45 years	46	34
35–44 years	41	39
< 35 years	13	27
Duration of antiviral therapy
≥ 5 years	59	41
1–5 years	31	49
< 1 year	10	10
Duration of LPV/r therapy
SGC > 1 year	82	80
Tablet < 3 months	89	81

ISSN: 1742-6405